A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN
Xiao W, Miles LA, Bowman RL, Durani V, Tian HS, DelGaudio NL, Mishra T, Zhu M, Zhang Y, Stump SE, Tallman MS, Levine RL, Cai SF
Blood Advances
Dec 2020
Abstract
Myeloid neoplasm (MPN) clones can evolve from acute myeloid leukemia to gain dominance with isocitrate dehydrogenase inhibition. Pro-differentiation agents such as ivosidenib can unmask MPN sequelae.
VIEW
Area
Heme
Institution Type
Academia
Indication / Modality
Acute Myleoid Leukemia (AML), Myeloproliferative Neoplasms (MPN)
Goal of Study
Therapeutic Resistance
Key Genes
JAK2, IDH1
PAD Project
No
Analytes Assessed
InDels, SNV
Sample Storage
Fresh Frozen
Sample Prep
Whole Cells
Sample Type
Patient Material
Tissue / Organ
Bone Marrow Aspirates
Species
Human
Panel Used
Custom
Proof Point Demonstrated
Clonality, Co-occurrence
